The disclosure relates to 2,6-diaminopurine compounds of formula (I) and compositions thereof for use in the treatment or prevention of retroviral infections in felines, in particular cats, and to the use of the compounds and compositions for the treatment or prevention of feline leukemia virus (FeLV) infections occurring alone or together with feline immunodeficiency virus (FIV) infections in cats.